Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCI -110 in Patients With Alzheimer's Disease and Agitation
NCT05239390Phase 2Unknown
- Sponsor
- Israeli Medical Center for Alzheimer's
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dronabinol + palmitoylethanolamide in agitation, sponsored by Israeli Medical Center for Alzheimer's. Status: unknown.
02
Drugs
dronabinol + palmitoylethanolamide
03
Conditions
agitation
Beyond the preview
Go deeper on NCT05239390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239390.